Literature DB >> 17975021

Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.

Soyoung Ko1, Liheng Shi, Soyoung Kim, Chung S Song, Bandana Chatterjee.   

Abstract

Increased androgen receptor (AR) levels are associated with prostate cancer progression to androgen independence and therapy resistance. Evidence has suggested that chronic inflammation is closely linked to various cancers including prostate cancer. Herein we show that the proinflammatory cytokine TNFalpha negatively regulates AR mRNA and protein expression and reduces androgen sensitivity in androgen-dependent LNCaP human prostate cancer cells. Decreased AR expression results from transcription repression involving essential in cis interaction of nuclear factor-kappaB (NF-kappaB) with the B-myb transcription factor at a composite genomic element in the 5'-untranslated region of AR. The negative regulation was abrogated when NF-kappaB activity was inhibited by a superrepressor of the inhibitory kappaB protein. In contrast, androgen-independent C4-2 (LNCaP-derived) cells fail to show AR down-regulation by TNFalpha, despite expression of B-myb and TNFalpha-induced NF-kappaB activity similar to that in LNCaP cells. The negatively regulated AR gene chromatin region showed TNFalpha-dependent enrichment of B-myb and the NF-kappaB proteins p65 and p50. In parallel, the histone deacetylase 1, corepressor silencing mediator of retinoid and thyroid hormone receptor and the corepressor-associated scaffold protein mSin3A were recruited to the inhibitory site. In C4-2 cells, neither NF-kappaB and B-myb, nor any of the corepressor components, were detected at the negative site in response to TNFalpha. Apoptosis was induced in TNFalpha-treated LNCaP cells, likely in part due to the down-regulation of AR. The androgen-independent, AR-expressing C4-2 and C4-2B (derived from C4-2) cells were resistant to TNFalpha-induced apoptosis. The results linking androgen dependence to the NF-kappaB and AR pathways may be insightful in identifying novel treatment targets for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975021      PMCID: PMC2234585          DOI: 10.1210/me.2007-0332

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  40 in total

1.  Mutual transcriptional interference between RelA and androgen receptor.

Authors:  J J Palvimo; P Reinikainen; T Ikonen; P J Kallio; A Moilanen; O A Jänne
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

2.  Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression.

Authors:  Raquel Sitcheran; Pankaj Gupta; Paul B Fisher; Albert S Baldwin
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

3.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

4.  An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1).

Authors:  Chung S Song; Ibtissam Echchgadda; Young-Kyo Seo; Taesung Oh; Soyoung Kim; Sung-A Kim; Sunghwan Cho; Liheng Shi; Bandana Chatterjee
Journal:  Mol Endocrinol       Date:  2005-12-15

Review 5.  Signal transduction in prostate cancer progression.

Authors:  Daniel Gioeli
Journal:  Clin Sci (Lond)       Date:  2005-04       Impact factor: 6.124

6.  Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Authors:  H C Wu; J T Hsieh; M E Gleave; N M Brown; S Pathak; L W Chung
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

7.  TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines.

Authors:  Dharam P Chopra; Raymond E Menard; Jakub Januszewski; Raymond R Mattingly
Journal:  Cancer Lett       Date:  2004-01-20       Impact factor: 8.679

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer.

Authors:  O Harris Ford; Christopher W Gregory; Desok Kim; Andrew B Smitherman; James L Mohler
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  Mithramycin targets sp1 and the androgen receptor transcription level-potential therapeutic role in advanced prostate cancer.

Authors:  Long G Wang; Anna C Ferrari
Journal:  Transl Oncogenomics       Date:  2006-10-11
View more
  18 in total

1.  Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase.

Authors:  Soyoung Ko; Jungmi Ahn; Chung S Song; Soyoung Kim; Katarzyna Knapczyk-Stwora; Bandana Chatterjee
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Androgen receptor levels are upregulated by Akt in prostate cancer.

Authors:  Susan Ha; Rachel Ruoff; Nicole Kahoud; Thomas F Franke; Susan K Logan
Journal:  Endocr Relat Cancer       Date:  2011-03-09       Impact factor: 5.678

3.  Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.

Authors:  Renee E Vickman; Jiang Yang; Nadia A Lanman; Gregory M Cresswell; Faye Zheng; Chi Zhang; R W Doerge; Scott A Crist; Andrew D Mesecar; Chang-Deng Hu; Timothy L Ratliff
Journal:  Mol Cancer Res       Date:  2019-03-01       Impact factor: 5.852

4.  RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.

Authors:  Shayna E Thomas-Jardin; Haley Dahl; Mohammed S Kanchwala; Freedom Ha; Joan Jacob; Reshma Soundharrajan; Monica Bautista; Afshan F Nawas; Dexter Robichaux; Ragini Mistry; Vanessa Anunobi; Chao Xing; Nikki A Delk
Journal:  Prostate       Date:  2019-11-15       Impact factor: 4.104

5.  Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.

Authors:  Julia A Staverosky; Xin-Hua Zhu; Susan Ha; Susan K Logan
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

Review 6.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

7.  Endotoxin-induced growth hormone resistance in skeletal muscle.

Authors:  Yu Chen; Sumita Sood; Vidya M R Krishnamurthy; Peter Rotwein; Ralph Rabkin
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

8.  Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.

Authors:  Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 9.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

10.  Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.

Authors:  Mallikarjuna Gu; Srirupa Roy; Komal Raina; Chapla Agarwal; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.